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Background: In cystic fibrosis (CF), chronic infection of the airways with Achromobacter xylosoxidans have become more frequent. The
pathogenic role of this is yet unclear.
Methods: A retrospective case-control study of all patients chronically infected with A. xylosoxidans for at least 3 years. 15 patients (6
males) with chronic A. xylosoxidans infection were matched by age, FEV1 and body mass index z-score to 15 controls (7 males) at the time
of establishment of chronic infection. Clinical parameters of the groups were compared from the time of establishment of chronic infection
until spring 2006, giving a follow-up time of 3–11 years. Chest X-rays taken 3 years prior to establishment of chronic infection and after 3
years of chronic infection were compared using a modified Brasfield score. Finally, strains from individual patients were analysed using
PFGE to investigate possible cross-infection.
Results: The median slope of decline of FEV1 in the case group changed from +3.1% to 0.5% predicted/year ( p <0.002). In the control
group, median slope of decline in FEV1 changed from +1.5% to 0.4% predicted/year (n.s.). Median slope of decline in FVC in the case
group changed from +3.5% to 0.5% predicted/year ( p <0.002). In the control group, median slope of decline in FVC changed from +1.7%
to +0.4% predicted/year (n.s.). No significant difference in the slopes of decline of FEV1 or FVC was found between the case group and the
control group at either time. Change in BMI z-score was calculated for each group before and during chronic infection. No difference was
found between the groups at any time or within a group. Specific antibodies against A. xylosoxidans were measured in patients with chronic
infection. Patients with rapidly increasing antibody levels showed significantly faster deterioration in FEV1 ( p <0.05) and FVC ( p <0.02).
Chest X-ray scores increased in 6 of 10 chronically infected patients and in 3 of 10 controls (n.s.).
Eight patients harboured a common A. xylosoxidans strain, indicating either cross-infection or a common source.
Conclusion: A. xylosoxidans may lead to a decline in lung function in a subgroup of chronically infected CF patients characterised by a
rapid increase in specific precipitating antibodies. Cross-infection may possibly occur.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Background
Several studies have shown the ability of Achromobacter
xylosoxidans to cause chronic colonization of airways of
patients suffering from cystic fibrosis [1–8].
A. xylosoxidans is isolated with increasing frequency in
CF patients all over the world. Identification of the
microorganism can be difficult and the prevalence of
respiratory tract infections caused by A. xylosoxidans might1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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E-mail address: christunte@hotmail.com (C. Rønne Hansen).be underestimated. The U.S. Cystic Fibrosis Foundation’s
National Patient Registry reported an increasing rate of
respiratory infection with A. xylosoxidans. Percentage of
patients harbouring A. xylosoxidans increased from 0.5% to
1.9% and to 2.7% in the years 1995, 1996 and 1997,
respectively, and further to 3.8% and 5.2% in 1999 and 2002
[9–13]. 8.7% of CF patients participating in a study of
aerosolised tobramycin taking place in 1995–1996 were
harbouring A. xylosoxidans [2]. A. xylosoxidans may possess
the ability to cause cross-infection between patients [3,7,14],
although some patients may be exposed to these micro-
organisms for a very long time before achieving infection [4].5 (2006) 245 – 251ed by Elsevier B.V. All rights reserved.
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number of patients becoming chronically infected with A.
xylosoxidans, the present study was carried out.
The aim of the present study is to describe the occurrence
of chronic infection with A. xylosoxidans in our CF centre,
to assess the importance of this infection on the progress of
CF lung disease and to evaluate the possibility of cross-
infection with this microorganism among CF patients.2. Materials and methods
2.1. Study design
A retrospective case-control study of CF patients treated
at the Copenhagen CF clinic and chronically infected with
A. xylosoxidans. The patients were followed in a 16 years
period, from 3 years before the first patient became
chronically infected (1990) until end of study period in
March 2006.
The diagnosis of CF was established on the basis of
abnormal sweat electrolytes, characteristic clinical features
and genotype.
2.2. Patients
All CF patients in the center are seen on a regular
monthly basis. At each visit, the clinical status of the
patients is assessed by weight, height and lung function
parameters (forced vital capacity (FVC) and forced expira-
tory volume in 1 s (FEV1), Pneumothac, Draeger). Lower
respiratory tract secretions are obtained by coughing
(sputum producers) or endo-laryngeal suction, and sputum
microbiology is carried out. Infection is considered chronic,
when an organism has been cultured for six consecutive
sputum samples (monthly) or less if there is a simultaneous
increase in precipitating antibodies against the specific
microorganism above normal level (0–1) [15].
All patients are treated according to fixed guidelines,
which include PEP mask, and, since 1994, daily adminis-
tration of Pulmozyme. A. xylosoxidans is treated at the first
isolate with 3 weeks of inhaled colistin and oral amoxicillin
with clavulanic acid. If this treatment is insufficient, i.e. the
microorganism is present in the next lower respiratory tract
secretion, the treatment is repeated, this time for 3 months.
If the infection fulfills the criteria for chronic infections, the
patients are treated with continuous inhaled and oral
antibiotics, depending on the resistance pattern of the
microorganism, and with elective courses of i.v. antibiotics
for 2 weeks every 3 months, similar to patients chronically
infected with Pseudomonas aeruginosa [16]. This treatment
strategy was not changed during the study period.
All patients chronically infected with A. xylosoxidans
were evaluated for inclusion in a case-control study. Only
patients chronically infected for at least 3 years were
included. All cases and controls were matched on age (T3years), gender, FEV1 (T10% predicted) at the time of
establishment of chronic A. xylosoxidans infection in the
case patients, and by co-infection with P. aeruginosa or
other gram-negative microorganisms. Patients chronically
co-infected with Burkholderia multivorans or Mycobacte-
rium abscessus were excluded from the study because of
difficulties in finding control subjects.
2.3. Changes in clinical parameters
FEV1 and FVC were expressed as slope of decline in a 3-
year period prior to establishment of chronic infection and in
the entire observation period (3–9 years) after establishment of
chronic infection. Change in nutritional status was expressed
as change in bodymass index (BMI) standard deviation scores
(z-scores) prior to and during chronic infection.
2.4. Chest X-rays
Two independent radiologists, blinded to status of
individual patients, scored chest X-rays obtained 3 years
before and 3 years after establishment of chronic infection.
All chest X-rays were taken during a stable period. We used
a modified Brasfield score [17], judging only the overall
severity of changes on roentgenograms, since the quality of
some of the old chest X-rays made it impossible to judge
scores on air trapping, linear markings, nodular-cystic
lesions and large lesions.
2.5. Cross-infection
Because of the rapidly increasing number of patients
chronically infected with A. xylosoxidans, pulsed field gel
electrophoresis (PFGE) [18] was done, if possible, on
strains isolated from individual patients.
2.6. Measurement of specific anti-achromobacter antibodies
Specific IgG anti-achromobacter antibodies were mea-
sured at least once a year, using the method described for P.
aeruginosa by crossed immunoelectrophoresis [19]. Normal
values: 0–1 precipitins.3. Statistical analysis
Gender and genotype in the case and control groups, and
speed of increase in precipitating antibodies in the two
groups colonized with unique and shared strains were
compared using chi-squared test.
Calculation of slope of decline in lung function was done
using linear regression analysis. All monthly performed
lung functions measured were included for calculation of
the slope of decline in the two time periods.
Change in body mass index (BMI) z-score was calcula-
ted using linear regression analysis. All monthly measure-
Table 1
Gender, FEV1 and age in the two groups
Cases Controls P-value
Number (males) 15 (6) 15 (7) n.s.
Diabetes 3 2 n.s.
Median FEV1
(% predicted),
no=13
87.8
(range 52.2–110.7)
90.8
(range 48.2–109.6)
n.s.
Median age, no=15 16.1
(range 6.6–27.8)
15.7
(range 7–35.9)
n.s.
C. Rønne Hansen et al. / Journal of Cystic Fibrosis 5 (2006) 245–251 247ments of height and weight were used to calculate the
change in BMI z-score.
Lung function and BMI z-score values were compared
using Student’s t-test: either paired t-test when comparing
data over time in a group or non-paired t-test when
comparing different groups. Level of significance <0.05
(two-tailed).
Chest X-ray scores were compared using Mann–Whit-
ney’s test when comparing groups and Wilcoxon signed
ranks test when comparing changes over time in a group.
Correlation between change in lung function and level of
precipitating antibodies was calculated using Pearson’s
correlation.4. Results
4.1. Patients
At the end of the study period, 22 of 284 CF patients
(current number) treated at the Copenhagen CF center (8%
of the entire population) had been chronically infected with
A. xylosoxidans (10 males). In Fig. 1, the cumulative
number of chronically infected patients in the entire study
period is illustrated. Of all chronically infected patients, 15
patients (6 males) fulfilled the inclusion criteria. Two
patients were not old enough to being able to perform lung
function measurement prior to establishment of chronic
infection, but were included for evaluation of nutritional
status. Five patients had been chronically infected for less
than 3 years and were not included. Two other patients were
co-infected with either B. multivorans, or M. abscessus,
which made it impossible to find controls of the same age,
sex, lung-function and these specific co-infections. Age,
FEV1, gender and number of patients with diabetes at the
time of inclusion in the study are shown in Table 1. All
patients included in the study were pancreas insufficient and
were carrying severe CF mutations. None of the patientsFig. 1. Cumulative number of patients chronically infected with A. xylosoxidans i
transplantation: one in 2002, after 6 years of chronic infection; one in 2005, aftechronically infected with A. xylosoxidans died during the
study period, but two patients had lung transplantation done
during the study period and were excluded from further
evaluation at that moment.
Median follow-up time after establishment of chronic
infection was 6 years (range 3–11).
Three of the 13 included patients had chronic co-infection
with P. aeruginosa. In two of these patients, sputum cultures
remained positive for P. aeruginosa after establishment of
chronic infection with A. xylosoxidans, and one patient has
only intermittently been carrying this microorganism after 3
years of chronic A. xylosoxidans infection.
4.2. Lung function
The changes in lung function in both case and control
groups in the 3-year period prior to as well as in the years
after establishment of chronic A. xylosoxidans are shown in
Figs. 2a–b and 3a–b.
We found no significant difference in FEV1, when
comparing the groups of cases and controls neither prior
to the study period, nor during the study period (Table 2).
However, FEV1 changed significantly within the case
group when comparing change in FEV1 prior to chronic
infection and during chronic infection ( p <0.002). This
was not the case in the control group (Table 2 and Fig.
2a–b).n the Copenhagen Cystic Fibrosis Centre. (j) Two patients have got lung
r 12 years of chronic infection.
Fig. 2. Change in FEV1 before and during chronic infection in case group (a) and control group (b).
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and during chronic infection in the case-group was
4.9% predicted/year (range 8.2 to +4.5) and in the
control-group 2% predicted/year (range 6.7 to +4.4)
( p <0.05).Fig. 3. Change in FVC before and during chronic infLikewise, we found no significant difference in FVC
when comparing the two groups neither prior to the study
period nor during the study period (Table 3).
However, the slope of FVC changed significantly
within the case group when comparing change in FVCection in case group (a) and control group (b).
Table 2
Median change in FEV1 (% predicted/year) before and during chronic
infection
3 years before During chronic infection P-value
Cases +3.1
(range 2.5 to +9.4)
0.5
(range 9.4 to +4.3)
<0.002
Controls +1.5
(range 8.4 to +6)
0.4
(range 4.9 to +2.7)
n.s.
P-value n.s. n.s.
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( p <0.002). This was not the case in the control group
(Table 3 and Fig. 3a–b).
The difference in change in FVC in the periods before
and during chronic infection in the case group was 4.5%
predicted/year (range 11.9 to +2.4) and 0.3% predicted/
year (range 14.9 to +4) in the control group (n.s.).
In the case group, the number of patients who had
decreasing levels of FEV1 and FVC before the chronic
infection was established was 4, and this number increased
to 9 and 8, respectively. In the control group, the number of
patients with decreasing levels of FEV1 and FVC before the
study period was 5 in both groups, and during the study
period 7 and 6, respectively.
4.3. Nutritional status expressed as BMI z-score
Median change in BMI z-score was 0.11/year (range
1.24 to +0.34) in the case group and 0.05/year (range
0.3 to +0.24) in the control group prior to the observation
period. During the study period, the nutritional status of the
patients improved both in case and control groups. Median
change in BMI z-score in the case group was +0.01/year
(range 0.27 to +0.27) and +0.02/year in the control group
(range 0.36 to +0.25). We found no significant difference
between or within the groups.
4.4. Chest X-ray scores
Pairs of chest X-rays were found on 20 of 30 patients: 10
in the case group and 10 in the control group. Possible range
of scores was 0–5. We found no patients with a score of 5. 3
years prior to chronic infection, the group of cases had a
median score of 2 (range 0–4) and the group of controls had
a median score of 1 (range 0–3) (n.s.). 3 years after chronic
infection, the case group had a median score of 3 (range 1–Table 3
Median change in FVC (% predicted/year) before and during chronic
infection
Before During chronic infection P-value
Cases +3.5
(range 2.6 to +8.4)
0.5
(range 10.9 to +4.3)
<0.002
Controls +1.7
(range 3.4 to +9.7)
+0.4
(range 5.2 to +3.5)
n.s.
P-value n.s. n.s.4) and the group of controls had a median score of 1 (range
0–4) (n.s.). We found no difference in scores within groups
over time. However, in the case group, six patients had
increasing scores over time, compared to three patients in
the control group.
4.5. Specific precipitating antibodies
The level of specific precipitating antibodies against A.
xylosoxidans increased during the first 3 years of chronic
infection (Table 4). The antibody levels increased to a
median of 7 precipitins (range 1–21) in the first year of
chronic infection and further to 14 (1–31) and 17 (1–34) in
the second and third years of chronic infection, respectively.
In the control group, the antibody level remained low (0–1
precipitins).
4.6. Correlation of levels of specific anti-achromobacter
antibodies and clinical condition of the patients
Patients with established chronic infection with A.
xylosoxidans could be subdivided into two groups: one with
a rapid increase in precipitating antibodies against A.
xylosoxidans to at least 15 during the first 3 years of infection
(N =7) and one with a slower increase in precipitating
antibodies (N =6). Median change in FEV1 in the group with
rapidly increasing antibodies was +2.4% predicted/year
(range 2.5 to +9.4) before chronic infection and decreased
to a median of2.3% predicted (range9.4 to +3.1) during
chronic infection ( p<0.02). Median change in FEV1 in the
other group was +3.9% predicted/year (range 0.2 to +7.7)
before chronic infection and changed to a median of +0.9%
predicted/year (range 1.3 to +4.3) during chronic infection
(n.s.). We found no difference between the two groups prior
to chronic infection, but during chronic infection the diffe-
rence was significant ( p <0.05). Correlation between level of
precipitating antibodies and change in FEV1 was highly
significant ( p<0.005) (Fig. 4).
Median change in FVC in the group with rapidly
increasing precipitating antibodies changed from +3.5%
predicted/year (range2.6 to +8.4) prior to chronic infection
to 3.7% predicted/year (range 10.9 to +1.4) during
chronic infection ( p <0.005). Median change in FVC in the
group with slowly increasing precipitating antibodies
changed from +4.2% predicted/year (range 0.3 to +8)
before chronic infection to +0.7% predicted/year (range
0.5 to +4.3) (n.s.). There was no difference between theTable 4
Level of specific anti-achromobacter precipitating antibodies in the years
after establishment of chronic infection
Year Median level (range) Number of patients
1 7 (1–21) 14
2 14 (1–31) 14
3 17 (1–34) 15
Fig. 4. Correlation between FEV1 and level of precipitating antibodies in the third year of chronic infection.
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infection the difference was significant ( p <0.02).
We found no difference between the two subgroups when
comparing change in BMI z-score.
4.7. PFGE
Isolates from 18 of 23 chronically infected patients (13 of
15 patients included in this study) were collected and typed
using pulsed field gel electrophoresis. We found eight patients
sharing the same strain, while 10 patients had individual
genotypes. One of the eight patients carrying the same
genotype is the index patient, chronically infected since 1993.
Of the eight patients carrying the cluster genotype, six
had a rapid increase in precipitating antibodies. Of the 10
patients carrying individual genotypes, four had a rapid
increase in precipitating antibodies (n.s.).5. Discussion
The present study calls attention to a new emerging
chronic infection, which affects an increasing number of CF
patients and which might have a negative influence on the
clinical course of disease.
A. xylosoxidans is a multi-resistant microorganism,
which makes antibiotic treatment difficult. In spite of early
and aggressive treatment, patients rapidly developed chronic
infection with A. xylosoxidans; in many patients in the case
group, the level of specific precipitating antibodies defined
chronic infection even after only a few positive sputum
cultures. Although we only have a small number of patients
in either group, we have followed the patients for a long
time after establishment of chronic infection.
Prior to establishment of chronic infection, the groups of
cases and controls in our study were in stable clinical
condition with stable lung function parameters. After
establishment of the chronic infection with A. xylosoxidans,the case group showed disease progression, particularly in a
subgroup of chronically infected patients. This group is
characterised by a more rapidly increasing level of specific
precipitating antibodies, which might be caused by either
more invasive infection due to an infection with a more
virulent strain, leading to a greater inflammatory response,
or a greater inflammatory response in general in this group
of patients. PFGE-typing of 18 strains found in our
population showed a cluster of eight patients harbouring
the same strain, indicating either that cross-infection had
occurred, or a common source of the infection. Transmis-
sible P. aeruginosa strains associated with more aggressive
infection have been reported [20].
In chronic infection caused by P. aeruginosa rapidly
increasing number of precipitins to P. aeruginosa has been
shown to be associated with poor prognosis [19]. The level
of specific, precipitating anti-achromobacter antibodies
increased much faster in our study group during chronic
infection when compared to the level of anti-pseudomonas
antibodies in the first years of chronic infection with P.
aeruginosa [21] despite similar intensive antibiotic treat-
ment. No significant correlation between occurrence of
similar strains and either deterioration in lung function or
levels of specific antibodies were found in the present
study. The small number of patients can be a possible
explanation.
Our observations can indicate that chronic infection with
A. xylosoxidans may have a clinically relevant impact on the
clinical condition of CF patients, especially when the
infection results in a pronounced antibody response, and is
caused by a transmissible strain.
Scoring of chest X-rays using a modified Brasfield score
showed no difference between the groups. There was a
tendency, however, that more patients in the case group had
an increase in score over time. The number of pairs of chest
X-rays scored were very small—only 10 pairs in each
group, and this might be the reason why the difference was
not significant.
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antibodies between patients carrying unique genotypes and
patients carrying shared genotype, but again the number of
patients in each investigated group was small.
Only a few other studies have been published on the effect
of establishment of chronic infection with A. xylosoxidans on
the course of CF disease [1,3–7,14,22,23]. Tan et al. [6]
observed a greater decline in FVC than FEV1 and, for both
parameters, a greater decline in the case group than in the
control group during 4 years of observation, even though this
difference was not statistically significant. Preliminary results
from a study by Romano et al. [5] likewise showed no
significant change in lung function in 15 patients chronically
infected with A. xylosoxidans. Dunne and Maisch [22] found
A. xylosoxidans in sputum from CF patients with exacer-
bations, but data on lung functions of these patients are not
shown and sputum samples from CF patients with no
respiratory symptoms were not investigated. Similar cases
with clinical symptoms in patients harbouring A. xylosox-
idans have been described by Romano et al. and by Abdul
Wahab et al. [1,5]. In a study by Burns et al. [2], the patients
included in a study of aerosolised tobramycin, where
inclusion criteria were chronic infection with P. aeruginosa
and FEV1 between 25% and 75% predicted, had a higher
percentage of sputum cultures positive for A. xylosoxidans
(8.7%) when compared to the Patient Registry Annual Report
of the Cystic Fibrosis Foundation from the same time period
(0.5% and 1.9%, respectively) [9,10]. One possible explana-
tion can be that patients with a preserved normal lung
function have lower occurrence of A. xylosoxidans. There are
other case reports on patients with rapid decline in lung
function and deterioration of the clinical status after acquiring
chronic A. xylosoxidans infection, even leading to death in
less than a year [5]. Interpretation of these data is difficult,
because most patients had chronic co-infection with P.
aeruginosa.6. Conclusion
A. xylosoxidans may be responsible for greater decline in
lung function, particularly in a subgroup of CF patients,
characterized by a rapid increase in precipitating antibodies.
Cross-infection may possibly occur. Study of disease progres-
sion in a larger group of CF patients infected with this
microorganism is desirable to substantiate our observation.References
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